Evaluating a new CAR-T cell treatment for relapsed B-cell leukemia

A Early Phase 1 Clinical Trial To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

This study is testing a new CAR-T cell treatment for people with relapsed B-cell leukemia to see if it is safe and effective.

Quick facts

• Phase: Early Phase 1
• Study type: Interventional
• Enrollment: 9 (estimated)
• Ages: 18 Years to 70 Years
• Sex: All
• Sponsor: Hrain Biotechnology Co., Ltd. (Industry-sponsored)
• Drugs / interventions: CAR-T, chemotherapy
• Locations: 1 site (Nanchang, Jiangxi)
• Trial ID: NCT05651191 on ClinicalTrials.gov

What this trial studies

This is a single-arm, open-label, dose-escalation trial aimed at assessing the safety, tolerability, and pharmacokinetic/pharmacodynamic characteristics of human CD19 targeted DASH CAR-T cells in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Eligible participants will undergo preconditioning chemotherapy followed by the infusion of the CAR-T cells. The study will monitor participants for adverse events and evaluate the efficacy of the treatment over time. Comprehensive eligibility assessments will be conducted, including physical exams and imaging tests.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 70 with relapsed or refractory B-cell acute lymphoblastic leukemia who have not responded to standard chemotherapy.

Not a fit: Patients who are not eligible due to contraindications for TKI therapy or those with certain mutations may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with difficult-to-treat B-cell acute lymphoblastic leukemia.

How similar studies have performed: Other studies utilizing CAR-T cell therapies have shown promising results in treating B-cell malignancies, indicating a potential for success with this approach.

Eligibility criteria

Inclusion Criteria:Subjects must meet all of the following criteria to be enrolled:

* 18 to 70 years old (including cut-off value), Male and female;
* Expected survival \> 12 weeks;
* ECOG score 0-1;
* Bone marrow examination clearly diagnosed as B-cell acute lymphoblastic leukemia, CD19 positive, and who met one of the following conditions:

  1. Those who failed to achieve CR after at least 2 courses of standard chemotherapy or had early relapse after complete remission (\<12 months) or late relapse after complete remission (≥ 12 months) and failed to achieve CR after 1 course of standard chemotherapy;
  2. For Ph+ ALL: in addition to receiving at least 2 courses of standard chemotherapy, at least two TKIs should be treated with no complete remission or relapse after complete remission; (Patients who cannot tolerate TKI therapy or have TKI treatment contraindications or have T315i mutation are excluded);
  3. Those who relapse after stem cell transplantation are not affected by previous treatments;
* The venous access required for collection can be established and leukapheresis can be carried according to the judgement of investigators;
* Liver, kidney and cardiopulmonary functions meet the following requirements:

  1. Serum creatinine ≤ 1.5×ULN;
  2. Left ventricular ejection fraction \> 50%;
  3. Baseline oxygen saturation \> 96%;
  4. Total bilirubin ≤ 2×ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3×ULN (As judged by the investigator, the elevation of transaminase caused by the ALL disease itself, ALT and AST ≤ 5×ULN);
* Able to understand and sign the Informed Consent Document.

Exclusion Criteria:Any one of the following conditions cannot be selected as a subject：

* Graft-versus-host disease (GVHD), or need to use immunosuppressants after transplantation;
* Patients with hyperleukocytosis (white blood cell count ≥ 50×10\^9/L) or whose disease progressed rapidly according to the investigator's judgment at the time of enrollment and cannot ensure the completion of a complete treatment cycle;
* Malignant tumors other than acute lymphoblastic leukemia within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, ductal carcinoma in situ after radical resection and thyroid cancer after radical resection;
* Subjects with positive Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titer detection higher than the lower limit of the research center can detect; hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; human immunodeficiency virus (HIV) antibody positive; syphilis detection positive;
* Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification ≥ III), need drug therapy of severe arrhythmia, liver, kidney, or metabolic disease;
* Active or uncontrollable infection requiring systemic therapy within 14 days prior to enrollment;
* Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pregnancy within 1 year after cell transfusion;
* Received CAR-T treatment or other gene therapies before enrollment;
* Patients with symptoms of central nervous system;
* Subjects who are receiving systemic steroid treatment and requiring long-term systemic steroid treatment during the treatment as determined by the investigator before screening (except inhalation or topical use);
* The investigators consider other conditions unsuitable for enrollment.

Where this trial is running

Nanchang, Jiangxi

• The Second Affiliated Hospital of Nanchang University — Nanchang, Jiangxi, China (Recruiting)

Study contacts

• Principal investigator: Qingming Wang, M.D. — Second Affiliated Hospital of Nanchang University
• Study coordinator: Xuedong Sun, M.D.

Conditions B-cell Acute Lymphoblastic Leukemia; CD19; CAR-T; B-cell acute lymphoblastic leukemia; Relapsed /Refractory